drugset / Trial / NCT03077217

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

NCT03077217

Phase 4 Completed 40 enrolled Shanghai Changzheng Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.

Timeline

Start
2017-05-01
Primary completion
2020-05-31
Completion
2020-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rifaximin Other / unclassified 800 mg
Comparator Rifaximin Other / unclassified 1200 mg